March 5 (Reuters) - Tenaya Therapeutics TNYA.O said on Thursday it has signed a research deal with Alnylam Pharmaceuticals ALNY.O worth up to $1.13 billion to develop treatments for heart diseases.

Shares of Tenaya were up more than 11% in premarket trading.

Here are some details:

• Tenaya said it will work on heart disease–focused treatments that target up to 15 genetic causes during a two‑year research period.

• Alnylam will handle all further drug development and take full responsibility for commercialization of any medicines that come out of the collaboration, Tenaya said.

• The company said it could receive up to $10 million in upfront payments and additional research funding from Alnylam. It may also be eligible for up to $1.13 billion in milestone payments if the drugs are successfully developed and approved.

• Alnylam's major growth driver is Amvuttra, which treats a heart condition known as transthyretin amyloid cardiomyopathy (ATTR-CM). Amvuttra recorded sales of $2.31 billion in 2025.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Devika Syamnath)

((Padmanabhan.Ananthan@thomsonreuters.com;))